BeyondSpring Announces Leadership Transition to Deliver Focused Execution on Its Confirmatory DUBLIN-4 Program and Long-Term Value

Phase 3PlinabulinNeutral

AI Analysis

Summary

BeyondSpring announced a leadership transition effective July 1, 2026, to focus on completing its Phase 3 DUBLIN-4 confirmatory program for Plinabulin in EGFR wild-type NSCLC post-ICI patients.

Clinical Trial Data

Phase

Phase 3

Importance:3/10

Sentiment:

0.00

Leadership TransitionDUBLIN-4Phase 3Confirmatory TrialNSCLC

Related Companies

$BYSI

Read the original article

Published by GlobeNewswire Pharma on June 4, 2026 11:00 AM

Read Original